These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 12407431)
1. Administration of low-dose interleukin-2 plus G-CSF/EPO early after autologous PBSC transplantation: effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer. Perillo A; Pierelli L; Battaglia A; Salerno MG; Rutella S; Cortesi E; Fattorossi A; De Rosa L; Ferraù F; Lalle M; Leone G; Mancuso S; Scambia G Bone Marrow Transplant; 2002 Nov; 30(9):571-8. PubMed ID: 12407431 [TBL] [Abstract][Full Text] [Related]
3. Low-dose cyclophosphamide in combination with cisplatin or epirubicin plus rhG-CSF allows adequate collection of PBSC for autotransplantation during adjuvant therapy for high-risk cancer. Menichella G; Pierelli L; Scambia G; Salerno G; Benedetti Panici P; Foddai ML; Serafini R; Puglia G; Lai M; Ciarli M Bone Marrow Transplant; 1994 Dec; 14(6):907-12. PubMed ID: 7536071 [TBL] [Abstract][Full Text] [Related]
4. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial. Vannucchi AM; Bosi A; Ieri A; Guidi S; Saccardi R; Lombardini L; Linari S; Laszlo D; Longo G; Rossi-Ferrini P Bone Marrow Transplant; 1996 Apr; 17(4):527-31. PubMed ID: 8722349 [TBL] [Abstract][Full Text] [Related]
5. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor. Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733 [TBL] [Abstract][Full Text] [Related]
6. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone. Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570 [TBL] [Abstract][Full Text] [Related]
7. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor. Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358 [TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
9. Immunological and clinical effects of post-transplant G-CSF versus placebo in T-cell replete allogeneic blood transplant patients: results from a randomized double-blind study. Joshi SS; Bishop MR; Lynch JC; Tarantolo SR; Abhyankar S; Bierman PJ; Vose JM; Geller RB; McGuirk J; Foran J; Bociek RG; Hadi A; Day SD; Armitage JO; Kessinger A; Pavletic ZS Cytotherapy; 2003; 5(6):542-52. PubMed ID: 14660050 [TBL] [Abstract][Full Text] [Related]
11. Circulation of progenitor cells after intensive chemotherapy followed by combination G-CSF and EPO in breast carcinoma. Filip S; Vanásek J; Bláha M; Vávrová J Neoplasma; 1997; 44(4):212-8. PubMed ID: 9473775 [TBL] [Abstract][Full Text] [Related]
12. Enhanced antileukemic activity of allogeneic peripheral blood progenitor cell transplants following donor treatment with the combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) in a murine transplantation model. Hartung G; Zeis M; Glass B; Dreger P; Steinmann J; Schmitz N; Uharek L Bone Marrow Transplant; 2003 Jul; 32(1):49-56. PubMed ID: 12815478 [TBL] [Abstract][Full Text] [Related]
13. Autologous peripheral blood stem cell transplantation and adoptive immunotherapy with activated natural killer cells in the immediate posttransplant period. Lister J; Rybka WB; Donnenberg AD; deMagalhaes-Silverman M; Pincus SM; Bloom EJ; Elder EM; Ball ED; Whiteside TL Clin Cancer Res; 1995 Jun; 1(6):607-14. PubMed ID: 9816022 [TBL] [Abstract][Full Text] [Related]
14. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial. Burns LJ; Weisdorf DJ; DeFor TE; Vesole DH; Repka TL; Blazar BR; Burger SR; Panoskaltsis-Mortari A; Keever-Taylor CA; Zhang MJ; Miller JS Bone Marrow Transplant; 2003 Jul; 32(2):177-86. PubMed ID: 12838283 [TBL] [Abstract][Full Text] [Related]
16. Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates. Meehan KR; Verma UN; Cahill R; Frankel S; Areman EM; Sacher RA; Foelber R; Rajagopal C; Gehan EA; Lippman ME; Mazumder A Bone Marrow Transplant; 1997 Oct; 20(8):643-51. PubMed ID: 9383227 [TBL] [Abstract][Full Text] [Related]
17. Delayed administration of G-CSF until day +7 after autologous peripheral blood stem cell transplant is as effective in accelerating hematopoietic as day 0. Sobrevilla-Calvo P; Zinser Sierra JW; Lara Medina FU; Acosta Barreda A; Calderón Flores E Rev Invest Clin; 2002; 54(1):51-6. PubMed ID: 11995407 [TBL] [Abstract][Full Text] [Related]
18. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation. Zumberg MS; Leather HL; Nejame C; Meyer C; Wingard JR Cytotherapy; 2002; 4(6):531-8. PubMed ID: 12568989 [TBL] [Abstract][Full Text] [Related]
19. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature. Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563 [TBL] [Abstract][Full Text] [Related]
20. The role of granulocyte colony-stimulating factor (G-CSF) in the post-transplant period. Hornedo J; Solá C; Solano C; López JJ; Alonso S; Lluch A; Ojeda B; Garcia-Conde J; Cortés-Funes H; Bone Marrow Transplant; 2002 May; 29(9):737-43. PubMed ID: 12040470 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]